The EC has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary ATTR-CM in adults.

The drug is already approved in the EU for transthyretin amyloidosis with polyneuropathy but now covers patients with cardiomyopathy.

Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Contrast Security, the global leader in Application Detection and Response (ADR), today announced the general availability of Northstar, a major release for the company that redefines how businesses ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...